BioLineRx (BLRX) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Join SI Premium – FREE
BioLineRx (NASDAQ: BLRX) reported Q2 EPS of $0.00, $0.14 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.39 million versus the consensus estimate of $2.94 million.
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- Moderna (MRNA) January 210 and 240 calls active amid wide price movement
- American Tower (AMT) PT Lowered to $220 at Citi
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
